

# NIRSEVIMAB

This guideline does not override the individual responsibility of health professionals to make appropriate decisions according to the circumstances of the individual patient in consultation with the patient and/or carer. Health care professionals must be prepared to justify any deviation from this guidance.

**The following National/Regional Guidance is adopted for use within the Trust**

– [NIRSEVIMAB Network Guidance 2025-28](#)

**This guidance is for use by the following staff groups:**

Neonatal Staff

<b>Specialty/Department/Service</b>	<b>Neonatal</b>
<b>Accountable committee/group</b>	<b>Paediatric Governance Group</b>
<b>Approved for use date</b>	<b>21st January 2026</b>

The table below highlights any sections of the national guidance, that the Trust has **not** adopted or unable to follow

<b>National Recommendation</b>	<b>Local Variation</b>	<b>Alternative key document</b>